-
TScan Therapeutics reaches agreement with US FDA on pivotal study design for TSC─101 and announces strategic prioritization to advance TSC─101
05 Nov 2025 12:45 GMT
… T) therapies for the treatment of patients with cancer … US Food and Drug Administration (FDA), the company has … preclinical development of in vivo engineering to treat solid … autoimmune diseases such as ankylosing spondylitis, systemic sclerosis, ulcerative …
-
Alvotech plant issues foil another FDA review, this time for Teva-partnered Simponi biosimilar
04 Nov 2025 14:10 GMT
… . commercialization, while Alvotech handles development and manufacturing of the partnered … and cleared to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative … issues with the FDA at its Icelandic drug plant. Since the …
-
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027
03 Nov 2025 11:30 GMT
… .S. Food and Drug Administration (FDA), the Company has … trial design for TSC-101, which is designed to treat … autoimmune diseases such as ankylosing spondylitis, systemic sclerosis, ulcerative colitis … candidate is in development for the treatment of patients …
-
Indian-origin researcher develops online tool for the early diagnosis of spinal arthritis
02 Nov 2025 20:51 GMT
… School of Medicine has developed a simple online screening … specialist care earlier when treatment is most effective. The … a family history of spondyloarthritis. The screening instrument purposely … with axSpA (7 with ankylosing spondylitis and 22 with non- …
-
Anti-Inflammatory Drugs Market to Reach USD 274.79 Billion by 2034, Fueled by Rising Innovation and Accessibility
31 Oct 2025 15:00 GMT
… Pharma aimed at transforming the landscape of anti-inflammatory therapeutics by developing … ankylosing spondylitis, rheumatoid arthritis, psoriasis, etc. By drug class, the nonsteroidal anti-inflammatory drugs …
-
<![CDATA[Bimekizumab and Patient-Reported Outcomes and Work Productivity in Patients With Psoriatic Arthritis | Written Recap]]>
05 Nov 2025 10:01 GMT
… the drugs lose efficacy over time, or treatments are discontinued … 17 when using these medications.”
The biological rationale for … and case series.
Trial design and results
The … Measure and the Bath Ankylosing Spondylitis Disease Activity Index.
Addressing …
-
MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab
05 Nov 2025 12:00 GMT
… .S. Food and Drug Administration (FDA), scheduled to be … 2 S-OLARIS trial in Axial Spondyloarthritis (axSpA) and … investigational Nanobody® for the treatment of inflammatory disease, to … : non-radiographic axSpA and ankylosing spondylitis (AS), also known as …
-
TNF Inhibitors Appear Safe in Pregnancy, Breastfeeding
04 Nov 2025 08:25 GMT
… or via breastfeeding used to treat women with various autoinflammatory … psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, and Crohn’s disease.
The … and benefits” of TNF inhibitor treatment during pregnancy.
SOURCE:
The study …
-
GLP-1s for diabetes reduce rheumatoid arthritis, gout risk
03 Nov 2025 13:38 GMT
… spondyloarthritis incidence was observed after use of GLP-1 drugs … adults starting treatment with GLP-1 … comorbidities, commonly used medications, and diabetes therapy. … , systemic lupus erythematosus, ankylosing spondylitis, scleroderma, psoriatic arthritis …
-
TIM-4 Regulates Allergic Airway Inflammation and Mast Cell Activation by Binding to CD300b
01 Nov 2025 23:10 GMT
… significantly inhibited the development of arthritis with a … Inflammation and mAb Treatment
Allergic airway inflammation … in patients receiving different medications. Patients with asthma … severity of patients with ankylosing spondylitis. Inflammation. 2015;38 …